Semaglutide and tirzepatide can both reduce appetite and support meaningful weight loss, but they are not the same medication. Semaglutide primarily works through the GLP-1 pathway. Tirzepatide acts on both GLP-1 and GIP receptors. That difference helps explain why their effects on appetite, blood sugar, and body weight are not identical.
The most direct comparison so far found greater average weight loss with tirzepatide than with the semaglutide doses studied. That does not mean tirzepatide is automatically the right choice for everyone. Medical history, side effects, other health conditions, medication form, cost, treatment goals, and the ability to stay on therapy all matter. Anyone considering either option should first understand what to know before starting a GLP-1 medication and have an individual medical review rather than choosing a drug based only on weight-loss percentages.
Semaglutide vs. Tirzepatide at a Glance
| Comparison | Semaglutide | Tirzepatide |
| How it works | Activates GLP-1 receptors | Activates both GIP and GLP-1 receptors |
| FDA-approved weight-management brand | Wegovy | Zepbound |
| Weight-management forms | Weekly injection; daily oral Wegovy is also available for adults | Weekly injection |
| What it may affect | Appetite, fullness, food intake, blood sugar | Appetite, fullness, food intake, blood sugar through two hormonal pathways |
| Head-to-head result | 13.7% average weight reduction in SURMOUNT-5 | 20.2% average weight reduction in SURMOUNT-5 |
| Common issues | Nausea, diarrhea, vomiting, constipation and other GI symptoms | Nausea, diarrhea, vomiting, constipation and other GI symptoms |
The 2025 SURMOUNT-5 trial compared weekly tirzepatide at maximum tolerated doses of 10 or 15 mg with weekly semaglutide at 1.7 or 2.4 mg. At 72 weeks, average weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide. The trial included adults with obesity without type 2 diabetes. That last detail matters. Clinical trial averages describe groups, not what any one person will lose.
How Do Semaglutide and Tirzepatide Work Differently?
Both medications influence signals between the digestive system and brain that help regulate appetite, food intake, and glucose metabolism.
Semaglutide Targets GLP-1
Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone involved in appetite regulation, insulin release, and digestion. Activating this pathway can help people feel satisfied with less food and may reduce hunger between meals.
For weight management, semaglutide is available in FDA-approved Wegovy formulations. By 2026, this includes weekly injections and an oral tablet for adults. The FDA also approved a higher-dose 7.2 mg Wegovy HD injection for certain adults in March 2026.
Tirzepatide Uses Two Hormonal Pathways
Tirzepatide activates GIP and GLP-1 receptors. GIP stands for glucose-dependent insulinotropic polypeptide. Like GLP-1, it plays a role in metabolic signaling. Using both pathways appears to produce a stronger average weight effect in the doses tested in the main head-to-head trial. However, greater average weight loss is only one factor in choosing treatment.
Patients who want to understand how medication fits into a broader plan can review the current approach to physician-guided medical weight loss and metabolic care.
Which One Causes More Weight Loss?
This is usually the first question people ask, and current evidence gives us a better answer than indirect comparisons did a few years ago.
What the Research Shows
| Study | Treatment Compared | Main Weight-Loss Finding | Study Length |
| STEP 1 | Semaglutide 2.4 mg vs. placebo | About 14.9% average weight reduction with semaglutide | 68 weeks |
| SURMOUNT-1 | Tirzepatide vs. placebo | About 15.0% to 20.9%, depending on dose | 72 weeks |
| SURMOUNT-5 | Tirzepatide vs. semaglutide | 20.2% vs. 13.7% average reduction | 72 weeks |
STEP 1 and SURMOUNT-1 were separate trials, so their percentages should not be treated as a perfect head-to-head comparison. SURMOUNT-5 is more useful for that question because participants were randomized directly to tirzepatide or semaglutide within the same study.
SURMOUNT-5 also found that 64.6% of participants receiving tirzepatide lost at least 15% of their body weight, compared with 40.1% receiving semaglutide. Waist circumference also decreased more in the tirzepatide group.
There Is an Important 2026 Catch
The semaglutide arm in SURMOUNT-5 used 1.7 mg or 2.4 mg weekly injections. It did not test the newer 7.2 mg Wegovy HD dose approved in 2026, and it did not compare tirzepatide against the newer daily oral Wegovy formulation.
So the most accurate conclusion is: Tirzepatide produced greater average weight loss than semaglutide 1.7/2.4 mg in the SURMOUNT-5 trial. That is more precise than saying tirzepatide will always produce more weight loss than every current form or dose of semaglutide.
Is More Weight Loss Always Better?
Not necessarily. A person who loses 12% of starting weight, feels well, preserves strength, improves blood pressure, and can stay on treatment may have a better outcome than someone who loses more weight but cannot tolerate the medication.
A good medical weight-loss plan looks beyond the scale. It may track:
- Waist measurement
- Blood pressure
- Blood glucose or A1C when relevant
- Cholesterol and triglycerides
- Energy and daily function
- Food intake and nutrition
- Strength and muscle preservation
- Medication tolerance
Weight loss also tends to slow after the early phase of treatment. If progress stalls, the answer is not automatically to increase the dose or switch medications. Nutrition, activity, adherence, sleep, other medications, and metabolic adaptation should be reviewed. Our guide to understanding a GLP-1 weight-loss plateau explains those factors in more detail.
Side Effects: Are Semaglutide and Tirzepatide Similar?
They share several side effects because both affect GLP-1 signaling and digestion.
Common problems may include:
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Stomach discomfort
- Indigestion or reflux
- Reduced appetite
In SURMOUNT-5, gastrointestinal symptoms were the most common adverse events with both medications and were usually mild to moderate. They occurred mainly while doses were being increased.
Both medications also carry more serious warnings and precautions. These include possible pancreatitis, gallbladder problems, kidney problems related to dehydration, severe gastrointestinal reactions, and hypoglycemia in certain people using other glucose-lowering medication. FDA-approved Wegovy and Zepbound also carry boxed warnings related to thyroid C-cell tumors observed in animal studies and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. A person’s complete medication list and health history should therefore be reviewed before treatment begins.
Some Health Conditions Can Change the Decision
Weight-loss percentage is not the only meaningful difference between these drugs. Semaglutide’s FDA-approved Wegovy labeling includes cardiovascular risk reduction for adults who have established cardiovascular disease and obesity or overweight. Wegovy injection also has an approved indication for certain adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.
Tirzepatide’s Zepbound labeling includes treatment of moderate to severe obstructive sleep apnea in adults with obesity, in addition to chronic weight management. These approved uses do not automatically determine which medication a person should take. They do show why two patients with the same weight may receive different recommendations. People who also have problems with glucose control may benefit from reading more about weight, metabolic health, and type 2 diabetes before discussing treatment goals.
What About Injection vs. Pill?
This comparison changed recently. Tirzepatide’s FDA-approved weight-management product, Zepbound, is administered by injection. Semaglutide now offers more flexibility because FDA-approved Wegovy is available as both an injection and a daily tablet for adults.
The oral tablet is not simply an injection placed into pill form. The dosing routine matters. FDA labeling instructs patients to take oral Wegovy in the morning on an empty stomach with no more than four ounces of water and then wait at least 30 minutes before food, other drinks, or oral medications. Someone who strongly dislikes injections may value an oral option. Someone who knows a strict daily morning routine would be difficult may prefer a weekly medication. The best format is the one that is medically appropriate and realistic enough to use correctly.
Pregnancy and Birth Control Deserve a Separate Conversation
These medications are not used for weight loss during pregnancy. FDA labeling for Wegovy advises stopping semaglutide at least two months before a planned pregnancy because the medication remains in the body for a long time.
Tirzepatide has an additional practical issue for people using oral hormonal contraceptives. Because it delays stomach emptying, its labeling advises switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting Zepbound and for four weeks after each dose increase. Anyone who is pregnant, planning pregnancy, breastfeeding, or using hormonal contraception should discuss these details before treatment.
Before Choosing Either Medication, Use This Checklist
A medication discussion becomes much more useful when it starts with the whole health picture.
Medical History Checklist
Before a prescription is selected, make sure your clinician knows about:
☐ Previous pancreatitis
☐ Gallbladder disease or gallstones
☐ Severe digestive problems or gastroparesis
☐ Kidney problems
☐ Diabetes and current diabetes medications
☐ Diabetic eye disease
☐ Personal or family history of medullary thyroid cancer
☐ MEN 2
☐ Pregnancy or plans for pregnancy
☐ Birth-control method
☐ Upcoming surgery or procedures requiring anesthesia
☐ Every prescription, OTC medication, and supplement you use
The patient FAQ page can also help answer practical questions about testing, prescriptions, referrals, and follow-up care.
Treatment-Fit Checklist
Then ask:
☐ What result are we actually trying to achieve?
☐ Which medication fits my medical history better?
☐ What side effects should I report?
☐ How slowly will my dose be increased?
☐ How will we protect nutrition and muscle while I lose weight?
☐ Which labs or measurements will be monitored?
☐ What happens if my weight stops changing?
☐ What is the total monthly cost, including medication?
☐ What happens if I need to stop treatment?
Current program and service costs can be reviewed on the weight-loss and membership pricing page before starting care.
A Note About Compounded Semaglutide and Tirzepatide
There is an important distinction between FDA-approved products and compounded medications.
FDA-approved Wegovy and Zepbound have gone through FDA review for their approved uses. Compounded drugs are not FDA approved, which means the agency does not review them for safety, effectiveness, and quality before marketing. In 2026, the FDA specifically advised that compounded GLP-1 drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved drug.
The clinical-trial percentages discussed above come from the studied FDA-approved medications and dosing regimens. They should not automatically be applied to a compounded version, a different concentration, or a different route of administration. FDA has also reported dosing errors and other concerns with compounded semaglutide and tirzepatide. Patients should use a prescription from a licensed clinician and obtain medication from an appropriately licensed pharmacy.
This makes physician supervision especially important. Patients can review the practice’s approach to medical weight-loss evaluation, monitoring, nutrition, and medication management before deciding whether to schedule an evaluation.
So, Which Is Better: Semaglutide or Tirzepatide?
There is no single answer for every patient.
Tirzepatide may deserve discussion when maximizing weight reduction is an important treatment goal and the person’s health history, tolerance, access, and other factors support its use. The strongest direct comparison to date found greater average weight loss with tirzepatide than with the semaglutide doses studied.
Semaglutide may deserve discussion when its approved indications, available forms, prior response, cardiovascular history, treatment preferences, or other clinical factors make it a better fit. The addition of oral Wegovy and Wegovy HD also means today’s semaglutide decision is broader than it was when older comparison articles were written. Neither decision should be reduced to “Which drug loses the most pounds?”
A better question is:
Which option offers the best balance of expected benefit, safety, tolerability, access, and long-term use for this particular person?
Do Not Forget the Part Medication Cannot Do
Medication can change hunger signals. It cannot build an entire long-term health plan on its own. Nutrition still needs enough protein, fiber, fluids, and micronutrients. Resistance exercise can help protect strength and lean tissue. Sleep and stress can affect appetite and daily habits. Follow-up matters when side effects appear or progress slows.
That is why medication works best inside a broader plan rather than as a stand-alone prescription. Readers interested in other aspects of metabolic and preventive care can explore the site’s full medical services or browse additional health and weight-management articles.
FAQs About Semaglutide vs. Tirzepatide
1. Is tirzepatide stronger than semaglutide for weight loss?
In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide 1.7 or 2.4 mg over 72 weeks. However, individual results vary, and that study did not evaluate the newer 7.2 mg Wegovy HD dose or oral Wegovy.
2. Are Ozempic and Wegovy the same as semaglutide?
They contain semaglutide but have different FDA-approved indications and dosing. Wegovy is the semaglutide brand approved for chronic weight management in eligible patients. Ozempic is primarily labeled for type 2 diabetes and certain related risk-reduction indications. Medication should be prescribed according to an individual’s medical situation.
3. Are Mounjaro and Zepbound the same as tirzepatide?
Both contain tirzepatide, but their approved uses differ. Zepbound is the tirzepatide product approved for chronic weight management in eligible adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is used for type 2 diabetes.
4. Can I switch from semaglutide to tirzepatide if my weight loss stops?
Possibly, but a plateau alone does not prove that the medication has stopped working. A clinician should first review dose, adherence, nutrition, activity, other medications, side effects, and possible medical causes. Never switch or increase a GLP-1/GIP medication without medical guidance.
5. How long do people stay on semaglutide or tirzepatide?
The answer depends on response, side effects, medical need, cost, and the treatment plan. Obesity is often managed as a chronic condition, so these medications should not be viewed automatically as short-term courses. Patients should discuss maintenance and what could happen after stopping before beginning therapy.
The Bottom Line
Semaglutide and tirzepatide belong to the same modern era of medical weight management, but they work differently and should not be treated as interchangeable.
Tirzepatide produced more average weight loss in the main direct comparison with semaglutide 1.7/2.4 mg. Semaglutide now has additional formulations and approved indications that can matter for individual patients. Side effects, other health conditions, pregnancy plans, medication access, and the ability to stay with treatment may be just as important as the percentage on a clinical-trial chart.
At Saguaro Direct Care, weight-loss treatment starts with physician evaluation rather than automatically selecting a medication. Patients considering semaglutide, tirzepatide, or another approach can review the medical weight-loss program, learn about the physicians on the care team page, or contact the practice to discuss next steps.